Time |
Tuesday, May 31 · 2:00pm - 3:00pm
|
---|---|
Location |
Online, register here: http://bit.ly/mg2SGn
|
Created By | |
More Info |
May 31, 2011 at 2:00 PM CDT | 3:00 PM EDT | 12:00 PM PDT
Please join us for a discussion on triple negative breast cancer (TNBC) and how it relates to those with BRCA genetic mutations. Anyone can get triple negative breast cancer, but research has shown that women who have BRCA1 mutations are at higher risk. So, what do you need to know? What can you do to help reduce your risk? What research is being done? Join us to find out. Our speakers for the hour will be Dr. Susan Domchek, a clinical researcher and Komen Scholar from the University of Pennsylvania, Sue Friedman, Executive Director of FORCE and survivor Laura Dubin. Register for this webinar here: http://bit.ly/mg2SGn This event is being streamed over the internet. It is recommended that you listen through your computer speakers. If for any reason you are unable to listen through your computer speakers, you can listen by telephone by calling: Backup Telephone: ( 877 ) 633 - 6595 Conference ID: 62717551 |
Taking you through my Journey to bring much awareness to Breast Cancer and that Early Detection is key to survival.
I promise
"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure
What is TNBC
WHAT IS TRIPLE NEGATIVE BREAST CANCER?
Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.
Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.